150 related articles for article (PubMed ID: 8957251)
1. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
McAllister KH
Eur J Pharmacol; 1996 Oct; 314(3):307-11. PubMed ID: 8957251
[TBL] [Abstract][Full Text] [Related]
2. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain.
Kaur S; Ozer H; Starr M
Eur J Pharmacol; 1997 Aug; 332(2):153-60. PubMed ID: 9286616
[TBL] [Abstract][Full Text] [Related]
3. Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats.
Bakshi VP; Tricklebank M; Neijt HC; Lehmann-Masten V; Geyer MA
J Pharmacol Exp Ther; 1999 Feb; 288(2):643-52. PubMed ID: 9918570
[TBL] [Abstract][Full Text] [Related]
4. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo.
Urwyler S; Campbell E; Fricker G; Jenner P; Lemaire M; McAllister KH; Neijt HC; Park CK; Perkins M; Rudin M; Sauter A; Smith L; Wiederhold KH; Müller W
Neuropharmacology; 1996 Jun; 35(6):655-69. PubMed ID: 8887975
[TBL] [Abstract][Full Text] [Related]
5. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
Tzschentke TM; Schmidt WJ
Eur J Pharmacol; 1996 Jan; 295(2-3):137-46. PubMed ID: 8720577
[TBL] [Abstract][Full Text] [Related]
6. State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801.
Schmidt WJ; Tzschentke TM; Kretschmer BD
Eur J Neurosci; 1999 Sep; 11(9):3365-8. PubMed ID: 10510204
[TBL] [Abstract][Full Text] [Related]
7. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
8. Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride).
Sun L; Chiu D; Kowal D; Simon R; Smeyne M; Zukin RS; Olney J; Baudy R; Lin S
J Pharmacol Exp Ther; 2004 Aug; 310(2):563-70. PubMed ID: 15075380
[TBL] [Abstract][Full Text] [Related]
9. Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
Melo LL; Santos P; Medeiros P; Mello RO; Ferrari EA; Brandão ML; Maisonnette SS; Francisco A; Coimbra NC
Brain Res; 2010 Aug; 1349():41-7. PubMed ID: 20558148
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of adenosine A2a receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-D-aspartate receptors.
Hauber W; Münkle M
Neurosci Lett; 1995 Aug; 196(3):205-8. PubMed ID: 7501284
[TBL] [Abstract][Full Text] [Related]
11. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
Moore NA; Blackman A; Awere S; Leander JD
Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205
[TBL] [Abstract][Full Text] [Related]
12. Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy.
Chartoff EH; Ward RP; Dorsa DM
J Pharmacol Exp Ther; 1999 Nov; 291(2):531-7. PubMed ID: 10525068
[TBL] [Abstract][Full Text] [Related]
13. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
Sevak RJ; Koek W; France CP
Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
[TBL] [Abstract][Full Text] [Related]
14. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
Karcz-Kubicha M; Lorenz B; Danysz W
Neuropharmacology; 1999 Jan; 38(1):109-19. PubMed ID: 10193902
[TBL] [Abstract][Full Text] [Related]
15. Glutamatergic neurotransmission in the inferior colliculus influences intrastriatal haloperidol-induced catalepsy.
Medeiros P; Viana MB; Barbosa-Silva RC; Tonelli LC; Melo-Thomas L
Behav Brain Res; 2014 Jul; 268():8-13. PubMed ID: 24667361
[TBL] [Abstract][Full Text] [Related]
16. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
[TBL] [Abstract][Full Text] [Related]
18. Electrical but not chemical kindling increases sensitivity to some phencyclidine-like behavioral effects induced by the competitive NMDA receptor antagonist D-CPPene in rats.
Wlaź P; Ebert U; Potschka H; Löscher W
Eur J Pharmacol; 1998 Jul; 353(2-3):177-89. PubMed ID: 9726648
[TBL] [Abstract][Full Text] [Related]
19. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
Papa SM; Engber TM; Boldry RC; Chase TN
Eur J Pharmacol; 1993 Mar; 232(2-3):247-53. PubMed ID: 8385618
[TBL] [Abstract][Full Text] [Related]
20. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Riedinger K; Kulak A; Schmidt WJ; von Ameln-Mayerhofer A
Behav Brain Res; 2011 Mar; 218(1):194-9. PubMed ID: 21130808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
